Rituximab Is Preferable to Cyclophosphamide for Treatment of Membranous Nephropathy: CON.
作者信息
van de Logt Anne-Els, Wetzels Jack F
机构信息
Department of Nephrology, Radboud Institute for Health Sciences, Radboud University Medical Center, Nijmegen, The Netherlands.
出版信息
Kidney360. 2021 Apr 19;2(11):1699-1701. doi: 10.34067/KID.0001432021. eCollection 2021 Nov 25.
Abstract
摘要
相似文献
1
Rituximab Is Preferable to Cyclophosphamide for Treatment of Membranous Nephropathy: CON.利妥昔单抗在治疗膜性肾病方面优于环磷酰胺：反对观点。
Kidney360. 2021 Apr 19;2(11):1699-1701. doi: 10.34067/KID.0001432021. eCollection 2021 Nov 25.
2
Rituximab Is Preferable to Cyclophosphamide for Treatment of Membranous Nephropathy: COMMENTARY.利妥昔单抗在治疗膜性肾病方面优于环磷酰胺：评论。
Kidney360. 2021 Apr 19;2(11):1702-1705. doi: 10.34067/KID.0002492021. eCollection 2021 Nov 25.
3
Rituximab Is Preferable to Cyclophosphamide for Treatment of Membranous Nephropathy: PRO.利妥昔单抗治疗膜性肾病优于环磷酰胺：支持观点。
Kidney360. 2021 Apr 19;2(11):1696-1698. doi: 10.34067/KID.0001842021. eCollection 2021 Nov 25.
4
Safety of Rituximab Compared with Steroids and Cyclophosphamide for Idiopathic Membranous Nephropathy.利妥昔单抗与类固醇及环磷酰胺治疗特发性膜性肾病的安全性比较
J Am Soc Nephrol. 2017 Sep;28(9):2729-2737. doi: 10.1681/ASN.2016091022. Epub 2017 May 9.
5
Immunosuppression therapy for idiopathic membranous nephropathy: systematic review with network meta-analysis.特发性膜性肾病的免疫抑制治疗：系统评价与网络荟萃分析。
J Nephrol. 2022 May;35(4):1159-1170. doi: 10.1007/s40620-022-01268-2. Epub 2022 Feb 23.
6
The STARMEN trial indicates that alternating treatment with corticosteroids and cyclophosphamide is superior to sequential treatment with tacrolimus and rituximab in primary membranous nephropathy.STARMEN 试验表明，在原发性膜性肾病中，与他克莫司和利妥昔单抗序贯治疗相比，皮质类固醇和环磷酰胺交替治疗更具优势。
Kidney Int. 2021 Apr;99(4):986-998. doi: 10.1016/j.kint.2020.10.014. Epub 2020 Nov 7.
7
Balancing cancer risk and efficacy of using cyclophosphamide to treat idiopathic membranous nephropathy.平衡使用环磷酰胺治疗特发性膜性肾病的癌症风险与疗效。
Clin J Am Soc Nephrol. 2014 Jun 6;9(6):1001-4. doi: 10.2215/CJN.04130414. Epub 2014 May 22.
8
Combination therapy with rituximab, low-dose cyclophosphamide, and prednisone for idiopathic membranous nephropathy: a case series.利妥昔单抗、低剂量环磷酰胺和泼尼松联合治疗特发性膜性肾病：病例系列
BMC Nephrol. 2017 Feb 1;18(1):44. doi: 10.1186/s12882-017-0459-z.
9
Idiopathic membranous nephropathy in children treated with rituximab: report of two cases.儿童特发性膜性肾病用利妥昔单抗治疗：两例报告。
Pediatr Nephrol. 2018 Jun;33(6):1089-1092. doi: 10.1007/s00467-018-3923-5. Epub 2018 Mar 15.
10
Efficacy and safety of rituximab therapy for membranous nephropathy: a meta-analysis.利妥昔单抗治疗膜性肾病的疗效和安全性：一项荟萃分析。
Eur Rev Med Pharmacol Sci. 2018 Nov;22(22):8021-8029. doi: 10.26355/eurrev_201811_16431.
引用本文的文献
1
Single-dose telitacicept therapy for refractory idiopathic membranous nephropathy: A case series.单剂量泰利西普治疗难治性特发性膜性肾病：病例系列
Clin Case Rep. 2024 Nov 6;12(11):e9553. doi: 10.1002/ccr3.9553. eCollection 2024 Nov.
2
Preliminary study on the efficacy of rituximab in the treatment of idiopathic membranous nephropathy: A single-centre experience.利妥昔单抗治疗特发性膜性肾病疗效的初步研究：单中心经验。
Front Endocrinol (Lausanne). 2023 Feb 15;14:1044782. doi: 10.3389/fendo.2023.1044782. eCollection 2023.
3
Rituximab Is Preferable to Cyclophosphamide for Treatment of Membranous Nephropathy: COMMENTARY.利妥昔单抗在治疗膜性肾病方面优于环磷酰胺：评论。
Kidney360. 2021 Apr 19;2(11):1702-1705. doi: 10.34067/KID.0002492021. eCollection 2021 Nov 25.
Zotero 插件